The Princeton Alpha Management LP Invests $407,000 in C R Bard Inc (BCR)

The Princeton Alpha Management LP Invests $407,000 in C R Bard Inc (BCR)

Several other large investors have also recently modified their holdings of the company. HPM Partners LLC purchased a new stake in shares of C R Bard during the first quarter worth approximately $3,828,000. Henderson Group PLC boosted its stake in shares of C R Bard by 7.5% in the first quarter. Henderson Group PLC now owns 229,858 shares of the medical instruments supplier’s stock worth $57,127,000 after buying an additional 15,978 shares during the last quarter. TIAA CREF Trust Co. FSB MO boosted its stake in shares of C R Bard by 16.0% in the first quarter. TIAA CREF Trust Co. FSB MO now owns 12,168 shares of the medical instruments supplier’s stock worth $3,024,000 after buying an additional 1,677 shares during the last quarter. Capital Fund Management S.A. boosted its stake in shares of C R Bard by 456.2% in the first quarter. Capital Fund Management S.A. now owns 45,465 shares of the medical instruments supplier’s stock worth $11,300,000 after buying an additional 37,291 shares during the last quarter. Finally, Moody Lynn & Lieberson LLC purchased a new stake in shares of C R Bard during the first quarter worth approximately $7,317,000. 86.89% of the stock is currently owned by institutional investors and hedge funds.

Princeton Alpha Management LP acquired a new position in C R Bard Inc (NYSE:BCR) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,638 shares of the medical instruments supplier’s stock, valued at approximately $407,000.

C R Bard Inc (NYSE:BCR) opened at 313.36 on Monday. The stock has a market cap of $22.69 billion, a price-to-earnings ratio of 39.88 and a beta of 0.63. The stock’s 50 day moving average price is $299.16 and its 200 day moving average price is $250.21. C R Bard Inc has a 12-month low of $203.63 and a 12-month high of $313.56.

C R Bard (NYSE:BCR) last posted its quarterly earnings data on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.22. C R Bard had a return on equity of 48.48% and a net margin of 14.31%. The business had revenue of $938.80 million during the quarter, compared to analysts’ expectations of $916.15 million. During the same quarter in the previous year, the firm earned $2.34 EPS. The firm’s revenue was up 7.5% compared to the same quarter last year. Analysts forecast that C R Bard Inc will post $11.78 EPS for the current fiscal year. The company also recently declared a quarterly dividend, which was paid on Friday, May 12th. Investors of record on Monday, May 1st were paid a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, April 27th. This represents a $1.04 annualized dividend and a yield of 0.33%. C R Bard’s dividend payout ratio is 14.77%.

C R Bard (NYSE:BCR) last posted its quarterly earnings data on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.22. C R Bard had a return on equity of 48.48% and a net margin of 14.31%. The business had revenue of $938.80 million during the quarter, compared to analysts’ expectations of $916.15 million. During the same quarter in the previous year, the firm earned $2.34 EPS. The firm’s revenue was up 7.5% compared to the same quarter last year. Analysts forecast that C R Bard Inc will post $11.78 EPS for the current fiscal year. A number of equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of C R Bard from a “buy” rating to a “hold” rating in a research note on Friday, May 12th. Raymond James Financial, Inc. cut shares of C R Bard from a “strong-buy” rating to a “mkt perform” rating in a research note on Wednesday, April 26th. Wells Fargo & Co cut shares of C R Bard from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 25th. BMO Capital Markets cut shares of C R Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price target on the stock. in a research note on Tuesday, April 25th. Finally, Morgan Stanley cut shares of C R Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. Twelve investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. C R Bard has a consensus rating of “Hold” and a consensus price target of $264.92.

In related news, VP Frank Lupisella, Jr. sold 3,622 shares of the business’s stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $304.00, for a total transaction of $1,101,088.00. Following the transaction, the vice president now directly owns 10,139 shares in the company, valued at $3,082,256. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.97% of the company’s stock. C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “BCR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment